Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01917942
Other study ID # TROG 07.03
Secondary ID
Status Completed
Phase Phase 3
First received August 1, 2013
Last updated July 10, 2017
Start date June 2008
Est. completion date August 2013

Study information

Verified date July 2017
Source Trans-Tasman Radiation Oncology Group (TROG)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two arm randomised phase III trial which will evaluate prospectively the benefits of humidification in patients receiving radiotherapy / chemoradiation for head and neck cancer. The intent of humidification is to moisturise the mucosa. The rationale for the use of humidification with radiotherapy can be considered an extension of the general principle of moist wound care in wound management.


Description:

This phase III trial will address four hypotheses. The primary hypothesis is:

Humidification will modulate the natural history of mucositis resulting in a clinically significant reduction in the intensity of severe acute mucositis as a function of time for CTCAE grade > 1 mucositis (e.g. grade 2 or higher), measured as the area under the time curve (AUC) of the plot expressing grade of acute reactions vs weeks for observed CTCAE mucosal reactions > 1

The additional hypotheses are:

- Humidification will palliate the acute symptoms of mucositis and xerostomia

- Humidification is cost effective through a reduction in hospital bed occupancy

- Humidification will improve the functional outcome, particularly swallowing function, of patients with head and neck cancer treated with radiotherapy


Other known NCT identifiers
  • NCT00598520

Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date August 2013
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Patients who meet the following criteria will be eligible:

- Pathologically confirmed diagnosis of cancer involving the Nasopharynx, Oropharynx, Oral Cavity, Larynx, or Hypopharynx

- Regional nodal irradiation included in PTV1 (as a minimum ipsilateral levels II-III)

- Prescribed dose of radiotherapy is at least 60 Gy

- Receiving definitive or post-operative adjuvant Radiotherapy

- Receiving Radiotherapy as sole modality or Chemoradiation

- Patient > 18 years old

- Available for follow-up for up to 2 years

- Life expectancy greater than 6 months

- Written informed consent

- Participation of patients on other clinical trial protocols permitted

Exclusion Criteria:

Patients who meet the following criteria will be excluded:

- Presence of tracheostomy or stoma

- Diagnosis of T1 / T2 glottic carcinoma

- Undergoing CPAP therapy -Treatment with Amifostine or Palifermin (keratinocyte growth factor) during radiotherapy

- History of previous radiotherapy to the head and neck region, excluding superficial radiotherapy to cutaneous squamous cell carcinoma or basal cell carcinoma

- High risk for poor compliance with radiotherapy, humidification, or follow-up as assessed by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Humidification
Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
Other:
Standard of Care
SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.

Locations

Country Name City State
New Zealand Auckland Hospital Auckland

Sponsors (3)

Lead Sponsor Collaborator
Trans-Tasman Radiation Oncology Group (TROG) Auckland City Hospital, Fisher and Paykel Healthcare

Country where clinical trial is conducted

New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intensity of mucositis as a function of time for CTCAE grade > 1 mucositis (e.g. grade 2 or higher) measured as the area under the time curve (AUC) of the plot expressing grade of acute reactions vs weeks for observed CTCAE mucosal reactions > 1. week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Terminated NCT01370876 - Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Terminated NCT03297957 - Fluorescence Imaging in Head and Neck Cancer N/A
Completed NCT00716157 - Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation N/A
Recruiting NCT04880148 - The Effectiveness of a Thyme and Honey Spray for Oral Toxicities N/A
Completed NCT01017224 - DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC) N/A
Completed NCT00496652 - DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Phase 3
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT03620084 - Effects of Expiratory Muscle Strength Training on Airway Protection and Swallowing in Chronic Dysphagia After Radiation Therapy N/A
Completed NCT00147472 - Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial) Phase 3
Completed NCT02880072 - Absorption of Orally Ingested Phosphate in Refeeding Syndrome Phase 4
Recruiting NCT04865731 - Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer Phase 2
Completed NCT02442336 - A Web-Based Multimedia Intervention for Head and Neck Cancer Patients N/A
Completed NCT03102229 - Real-time Activity Monitoring to Prevent Admissions During RadioTherapy N/A
Completed NCT00474825 - Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck Phase 1
Recruiting NCT00180921 - Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Completed NCT01283334 - A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT02557048 - Head and Neck Cancer in Children: A Retrospective Study
Completed NCT02073032 - Incidence and Risk Factors of Refeeding Syndrome N/A
Active, not recruiting NCT02270814 - Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma Phase 2